on Zomedica Corp. (NASDAQ:ZOM)
Zomedica Expands TRUFORMA Platform with Two New Canine Assays
Zomedica Corp., a veterinary health company, has launched two new assays for its TRUFORMA In-Clinic Biosensor Testing Platform. These assays, NT-proBNP and progesterone, increase the platform's diagnostic capabilities. NT-proBNP aids in identifying heart disease in dogs, offering quick results and lab-level accuracy. It helps distinguish cardiac issues from respiratory conditions and assists in diagnosing congestive heart failure.
The progesterone test detects hormone levels, helping determine optimal breeding times and diagnosing reproductive disorders. This new test responds to high demand, as it provides accurate results at the clinic, enhancing breeding success. Zomedica's latest additions continue its efforts to improve diagnostic solutions, delivering swift, precise results while ensuring financial ease for veterinary practices.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Zomedica Corp. news